{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:33:34Z","timestamp":1768437214704,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00854-3","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T04:32:44Z","timestamp":1762662764000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-6573","authenticated-orcid":false,"given":"Feliciana","family":"Menna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucilla","family":"Barbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Dell\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Ziccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"15\u201316","key":"854_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s10354-012-0123-y","volume":"162","author":"F Fazekas","year":"2012","unstructured":"Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, et al. Fingolimod in the treatment algorithm of relapsing-remitting multiple sclerosis: a statement of the Central and East European (CEE) MS expert group. Wien Med Wochenschr. 2012;162(15\u201316):354\u201366.","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"854_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","volume":"30","author":"SF Hunter","year":"2016","unstructured":"Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs. 2016;30(2):135\u201347.","journal-title":"CNS Drugs"},{"issue":"8","key":"854_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","volume":"25","author":"LJ Scott","year":"2011","unstructured":"Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(8):673\u201398.","journal-title":"CNS Drugs"},{"issue":"2","key":"854_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40120-019-00162-7","volume":"8","author":"F Sica","year":"2019","unstructured":"Sica F, Centonze D, Buttari F. Fingolimod immune effects beyond its sequestration ability. Neurol Ther. 2019;8(2):231\u201340.","journal-title":"Neurol Ther"},{"issue":"3","key":"854_CR5","first-page":"119","volume":"13","author":"M Behjati","year":"2014","unstructured":"Behjati M, Etemadifar M, Abdar Esfahani M. Cardiovascular effects of fingolimod: a review article. Iran J Neurol. 2014;13(3):119\u201326.","journal-title":"Iran J Neurol"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.msard.2016.04.002","volume":"8","author":"A Meissner","year":"2016","unstructured":"Meissner A, Limmroth V. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS). Mult Scler Relat Disord. 2016;8:19\u201326.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"854_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/eye.2016.258","volume":"31","author":"P Mandal","year":"2017","unstructured":"Mandal P, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y. Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye (London). 2017;31(2):232\u201340.","journal-title":"Eye (London)"},{"issue":"5","key":"854_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/CPJ.0000000000000027","volume":"4","author":"S Cugati","year":"2014","unstructured":"Cugati S, Chen CS, Lake S, Lee AW. Fingolimod and macular edema: pathophysiology, diagnosis, and management. Neurol Clin Pract. 2014;4(5):402\u20139.","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"854_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","volume":"78","author":"N Jain","year":"2012","unstructured":"Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78(9):672\u201380.","journal-title":"Neurology"},{"key":"854_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102125","volume":"42","author":"LY Goh","year":"2020","unstructured":"Goh LY, Kirthi V, Silber E, Harvey JP, Jackson TL. Real-world incidence of fingolimod-associated macular oedema. Mult Scler Relat Disord. 2020;42:102125.","journal-title":"Mult Scler Relat Disord"},{"key":"854_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.918086","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Deng Z, Song L, Sun W, Zhao S. Diagnosis and management of fingolimod-associated macular edema. Front Neurol. 2022;13:918086.","journal-title":"Front Neurol"},{"issue":"8","key":"854_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243207","volume":"14","author":"GC Pratima","year":"2021","unstructured":"Pratima GC, Benita D, Sarkar S, Deb AK. Fingolimod-associated central serous chorioretinopathy in a young girl. BMJ Case Rep. 2021;14(8):e243207.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"854_CR13","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1097\/WNO.0000000000000937","volume":"41","author":"L Ziccardi","year":"2021","unstructured":"Ziccardi L, Landi D, De Geronimo D, Barbano L, Giorno P, Marfia GA, et al. Choriocapillaris integrity in relapsed central serous chorioretinopathy in a patient treated with fingolimod for multiple sclerosis: new insights from optical coherence tomography angiography. J Neuro-Ophthalmol. 2021;41(1):e51\u20133.","journal-title":"J Neuro-Ophthalmol"},{"issue":"7","key":"854_CR14","volume":"15","author":"AA Khan","year":"2023","unstructured":"Khan AA, Gutlapalli SD, Sohail M, Patel P, Midha S, Shukla S, et al. Fingolimod-associated macular edema in the treatment of multiple sclerosis. Cureus. 2023;15(7):e41520.","journal-title":"Cureus"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12886-015-0125-9","volume":"15","author":"N Ueda","year":"2015","unstructured":"Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis: a case report. BMC Ophthalmol. 2015;15:135.","journal-title":"BMC Ophthalmol"},{"key":"854_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2017.03.005","volume":"14","author":"A Kal","year":"2017","unstructured":"Kal A, O\u011fuz Ulusoy M, Horasanl\u0131 B, Cezairlio\u011flu \u015e, Kal \u00d6. Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;14:4\u20137.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"854_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/WNO.0000000000000592","volume":"38","author":"KS Khimani","year":"2018","unstructured":"Khimani KS, Foroozan R. Central serous chorioretinopathy associated with fingolimod treatment. J Neuroophthalmol. 2018;38(3):337\u20138.","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"854_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"854_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"5","key":"854_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","volume":"168","author":"J Camm","year":"2014","unstructured":"Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014;168(5):632\u201344.","journal-title":"Am Heart J"},{"issue":"6","key":"854_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1089\/jir.2022.0078","volume":"43","author":"T Hach","year":"2023","unstructured":"Hach T, Shakeri-Nejad K, Bigaud M, Dahlke F, de Micco M, Petricoul O, et al. Rationale for use of sphingosine-1-phosphate receptor modulators in COVID-19 patients: overview of scientific evidence. J Interferon Cytokine Res. 2023;43(6):246\u201356.","journal-title":"J Interferon Cytokine Res"},{"issue":"10","key":"854_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbalip.2014.06.012","volume":"1841","author":"BA Wilkerson","year":"2014","unstructured":"Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta. 2014;1841(10):1403\u201312.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"854_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-024-00645-4","volume":"12","author":"Y Abi Zeid Daou","year":"2024","unstructured":"Abi Zeid Daou Y, Lidouren F, Bois A, Watanabe N, Jendoubi A, Faucher E, et al. Investigation of fingolimod-induced lymphocyte sequestration on inflammatory response and neurological damages after cardiac arrest. Intensive Care Med Exp. 2024;12(1):57.","journal-title":"Intensive Care Med Exp"},{"key":"854_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577065","volume":"337","author":"M K\u00fcrt\u00fcnc\u00fc","year":"2019","unstructured":"K\u00fcrt\u00fcnc\u00fc M, Y\u0131lmaz V, Ak\u00e7ay H\u0130, T\u00fcrko\u011flu R, Altunrende B, \u00c7\u0131nar SA, et al. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing-remitting multiple sclerosis patients. J Neuroimmunol. 2019;337:577065.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"854_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","volume":"328","author":"A Groves","year":"2013","unstructured":"Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1\u20132):9\u201318.","journal-title":"J Neurol Sci"},{"issue":"12","key":"854_CR26","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.biochi.2012.07.002","volume":"94","author":"Y Mousseau","year":"2012","unstructured":"Mousseau Y, Mollard S, Richard L, Nizou A, Faucher-Durand K, Cook-Moreau J, et al. Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cells by down-regulating the S1PR1\/S1PR3 pathway. Biochimie. 2012;94(12):2523\u201331.","journal-title":"Biochimie"},{"issue":"8","key":"854_CR27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1194\/jlr.R046300","volume":"55","author":"VA Blaho","year":"2014","unstructured":"Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55(8):1596\u2013608.","journal-title":"J Lipid Res"},{"key":"854_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fneur.2019.00763","volume":"10","author":"R Fukai","year":"2019","unstructured":"Fukai R, Takahashi K, Abe H, Higashiyama Y, Doi H, Takeuchi H, et al. Non-traumatic acute epidural hematoma in multiple sclerosis treated with fingolimod. Front Neurol. 2019;10:763.","journal-title":"Front Neurol"},{"issue":"5","key":"854_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12443","volume":"22","author":"S Simula","year":"2017","unstructured":"Simula S, Laitinen TP, Laitinen TM, Hartikainen P, Hartikainen JEK. Sequence of cardiovascular autonomic alterations after fingolimod initiation. Ann Noninvasive Electrocardiol. 2017;22(5):e12443.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"854_CR30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/ijms19030718","volume":"19","author":"X Zhang","year":"2018","unstructured":"Zhang X, Seo Y, Silangcruz J, Zhang Y, Lee J, Wang J. Sphingosine-1-phosphate signaling in retinal diseases. Int J Mol Sci. 2018;19:718.","journal-title":"Int J Mol Sci"},{"key":"854_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/WNO.0000000000000864","volume":"41","author":"R Di Marco","year":"2021","unstructured":"Di Marco R, Costa G, Schillaci R, Giordano A, Reibaldi M, Parisi G. Ophthalmic complications associated with Fingolimod: a review of the literature and proposed mechanisms. J Neuroophthalmol. 2021;41:29\u201335.","journal-title":"J Neuroophthalmol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00854-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:53Z","timestamp":1768398713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00854-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Feliciana Menna, Lucilla Barbano, Carmen Dell\u2019Aquila, Mattia D\u2019Andrea, Vincenzo Parisi and Lucia Ziccardi declare that they have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the tenets of the Declaration of Helsinki (1964 and later amendments). Ethical approval was waived by the institutional ethics committee of IRCCS-Fondazione Bietti (Rome, Italy) because this study involved a retrospective review of anonymized patients\u2019 data under clinical out-patient evaluation. Patients were informed and consented to the use his\/her medical records and data for scientific purposes. Written informed consent has been obtained from each patient for publication of data. Explicit permission was obtained to publish the OCT and OCTA scans by the subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}